noscript

News and Announcements

Prescient Therapeutics Appoints Steven Yatomi-Clarke as CEO

  • Published February 15, 2016 12:37PM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

15th February 2016, ASX Announcement

Clinical stage oncology company, Prescient Therapeutics Ltd (PTX) is pleased to advise that it has appointed Steven Yatomi-Clarke as Chief Executive Officer and Managing Director of the Company.

Steven has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies. Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.

Steven leaves behind a very successful career as Director in Corporate Finance of leading Australian broker,  Patersons  Securities. Steven said, “I’m honoured to accept the invitation to lead PTX.  The impeccable science  behind  our  programs;the  world  class  scientific  and  clinical  personnel  involved and the fact  that our programs are already in several clinical trials with imminent catalysts made  it an opportunity that was impossible to resist.”

To read the full announcement, please click here.

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now